Please wait a minute...

Frontiers of Medicine

Front Med    2012, Vol. 6 Issue (3) : 317-321     DOI: 10.1007/s11684-012-0203-9
RESEARCH ARTICLE |
Potential indicators predict progress after surgical resection of gastrointestinal stromal tumors
Qinggang Hu, Shanglong Liu, Jianwei Jiang, Chen Zhang, Xiaowei Liu, Qichang Zheng()
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Download: PDF(141 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

In order to find out the potential indicators predicting prognosis of malignant gastrointestinal stromal tumors (GISTs) after surgical resection, we collected clinical records of 80 patients with malignant GISTs. Tumor location, size, mitotic index, necrosis were compared with the prognosis of malignant GISTs by Kaplan-Meier method and log-rank test. After a median follow-up of 844 days (52–2 145), we found that as National Institutes of Health suggested, tumors with intermediate risk had more favorable prognosis than that with high risk. Their 3-year survival rate were 65.3% and 41.3%, respectively (P<0.001). Moreover, tumor size and mitotic index were associated with free survival. The 3-year survival rate for patients with tumor size≤10 cm and>10 cm were 62.3% and 41.8%, respectively (P = 0.002), Tumors with mitotic index≤5/50 HPF had a higher 3-year survival rate than tumors with mitotic index>5/50 HPF (67.1% versus 40.7%, P = 0.005). The presence of necrosis was directly related to the malignant behavior. The 3-year survival rate for presence and absence necrosis were 50.8% and 64.8% (P = 0.008). From the present study, we can conclude that besides tumors size and mitotic index, tumor location and necrosis also influence on the long-term survival of patient with malignant GISTs after surgical resection.

Keywords gastrointestinal stromal tumors      surgery      survival     
Corresponding Authors: Zheng Qichang,Email:zhengqichang@yahoo.cn   
Issue Date: 05 September 2012
 Cite this article:   
Jianwei Jiang,Chen Zhang,Xiaowei Liu, et al. Potential indicators predict progress after surgical resection of gastrointestinal stromal tumors[J]. Front Med, 2012, 6(3): 317-321.
 URL:  
http://journal.hep.com.cn/fmd/EN/10.1007/s11684-012-0203-9
http://journal.hep.com.cn/fmd/EN/Y2012/V6/I3/317
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Jianwei Jiang
Chen Zhang
Xiaowei Liu
Qichang Zheng
Qinggang Hu
Shanglong Liu
Fig.1  Age and gender distributions of patients with malignant GISTs.
FactorsNumber of cases
Gender
Female42 (52.5%)
Male38 (47.5%)
Age
≤60 years56 (70%)
&gt;60 years24 (30%)
Symptom
Present65 (81.3%)
Absent15 (18.7%)
Site of origin
Stomach26 (32.5%)
Small intestine31 (38.7%)
Rectum10 (12.5%)
Others13 (16.3%)
Mitotic index
≤5/50 HPF55 (68.7%)
&gt;5/50 HPF25 (31.3%)
Tumor size
≤5 cm7 (8.8%)
&gt;5 cm and≤10 cm45 (56.2%)
&gt;10 cm28 (35.0%)
Necrosis
Present45 (56.7%)
Absent35 (43.7%)
Invasion
Present23 (28.7%)
Absent57 (71.3%)
Recurrence after surgery
Yes18 (22.5%)
No62 (77.5%)
Tab.1  Clinical data of patients with malignant GISTs
Fig.2  Survival of patients with intermediate risk versus patients with high risk GISTs.
Fig.3  Survival of malignant GISTs in different locations (stomach versus small intestine).
Fig.4  Survival of patients with malignant GISTs based on tumor size (size≤10 cm versus size>10 cm).
Fig.5  Survival of patients with malignant GISTs based on mitotic index.
Fig.6  Survival of patients with malignant GISTs based on necrosis (absence of necrosis versus presence of necrosis).
1 Zabka J. Gastrointestinal stromal tumors. Klin Onkol 2011; 24(3): 187–194 (in Czech)
pmid:21717788
2 Liu SL, Song ZF, Li W, Liu XW, Zhang C, Zheng QC. A clinicopathologic andimmunohistochemical study of gastrointestinal stromal tumors based on 122 cases. Chinese-German J Clin Oncol 2010; 9(10): 597–600
doi: 10.1007/s10330-010-0680-8
3 Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int 2006; 56(1): 1–9
doi: 10.1111/j.1440-1827.2006.01924.x pmid:16398673
4 Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279(5350): 577–580
doi: 10.1126/science.279.5350.577 pmid:9438854
5 Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299(5607): 708–710
doi: 10.1126/science.1079666 pmid:12522257
6 Mochizuki Y, Kodera Y, Ito S, Yamamura Y, Kanemitsu Y, Shimizu Y, Hirai T, Yasui K, Inada K, Kato T. Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach. World J Surg 2004; 28(9): 870–875
doi: 10.1007/s00268-004-7418-0 pmid:15593459
7 Keun Park C, Lee EJ, Kim M, Lim HY, Choi DI, Noh JH, Sohn TS, Kim S, Kim MJ, Lee HK, Kim KM. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 2008; 247(6): 1011–1018
doi: 10.1097/SLA.0b013e3181724f9d pmid:18520229
8 Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in pre-imatinib mesylate era. Cancer 2005; 103(4): 821–829
doi: 10.1002/cncr.20862 pmid:15648083
9 Bertolini V, Chiaravalli AM, Klersy C, Placidi C, Marchet S, Boni L, Capella C. Gastrointestinal stromal tumors—frequency, malignancy, and new prognostic factors: the experience of a single institution. Pathol Res Pract 2008; 204(4): 219–233
doi: 10.1016/j.prp.2007.12.005 pmid:18304753
10 Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33(5): 478–483
doi: 10.1053/hupa.2002.124123 pmid:12094372
11 Tryggvason G, Kristmundsson Ρ, ?rvar K, Jónasson JG, Magnússon MK, Gíslason HG. Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990-2003. Dig Dis Sci 2007; 52(9): 2249–2253
doi: 10.1007/s10620-006-9248-4 pmid:17420941
12 Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006; 244(2): 176–184
doi: 10.1097/01.sla.0000218080.94145.cf pmid:16858179
13 Kontogianni-Katsarou K, Lariou C, Tsompanaki E, Vourlakou C, Kairi-Vassilatou E, Mastoris C, Pantazi G, Kondi-Pafiti A. KIT-negative gastrointestinal stromal tumors with a long term follow-up: a new subgroup does exist. World J Gastroenterol 2007; 13(7): 1098–1102
pmid:17373746
14 Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v98–v102
doi: 10.1093/annonc/mdq208 pmid:20555113
15 Yamamoto H, Kojima A, Miyasaka Y, Imamura M, Nakamura N, Yao T, Tsuneyoshi M, Oda Y. Prognostic impact of blood vessel invasion in gastrointestinal stromal tumor of the stomach. Hum Pathol 2010; 41(10): 1422–1430
doi: 10.1016/j.humpath.2010.02.013 pmid:20573370
16 Greenson JK. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol 2003; 16(4): 366–375
doi: 10.1097/01.MP.0000062860.60390.C7 pmid:12692202
17 Dirnhofer S, Leyvraz S. Current standards and progress in understanding and treatment of GIST. Swiss Med Wkly 2009; 139(7-8): 90–102
pmid:19234877
18 Hassan I, You YN, Shyyan R, Dozois EJ, Smyrk TC, Okuno SH, Schleck CD, Hodge DO, Donohue JH. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008; 15(1): 52–59
doi: 10.1245/s10434-007-9633-z pmid:18000711
19 Haller F, Happel N, Schulten HJ, von Heydebreck A, Schwager S, Armbrust T, Langer C, Gunawan B, Doenecke D, Füzesi L. Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors. Mod Pathol 2007; 20(10): 1103–1111
doi: 10.1038/modpathol.3800947 pmid:17673922
20 Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003; 54(1): 3–24
pmid:12817876
21 Hoeben A, Sch?ffski P, Debiec-Rychter M. Clinical implications of mutational analysis in gastrointestinal stromal tumours. Br J Cancer 2008; 98(4): 684–688
doi: 10.1038/sj.bjc.6604217 pmid:18253129
22 Calabuig-Fari?as S, López-Guerrero JA, Navarro S, Machado I, Poveda A, Pellín A, Llombart-Bosch A. Evaluation of prognostic factors and their capacity to predict biological behavior in gastrointestinal stromal tumors. Int J Surg Pathol 2011; 19(4): 448–461
doi: 10.1177/1066896911402327 pmid:21427092
23 Hueman MT, Schulick RD. Management of gastrointestinal stromal tumors. Surg Clin North Am 2008; 88(3): 599–614, vii
doi: 10.1016/j.suc.2008.03.001 pmid:18514701
24 Parfitt JR, Streutker CJ, Riddell RH, Driman DK. Gastrointestinal stromal tumors: a contemporary review. Pathol Res Pract 2006; 202(12): 837–847
doi: 10.1016/j.prp.2006.08.006 pmid:17064855
25 Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2001; 8(3): 252–261
pmid:11378651
26 Sanchez Hidalgo JM, Rufian Pe?a S, Ciria Bru R, Naranjo Torres A, Mu?oz Casares C, Ruiz Rabelo J, Brice?o Delgado J. Gastrointestinal stromal tumors (GIST): a prospective evaluation of risk factors and prognostic scores. J Gastrointest Cancer 2010; 41(1): 27–37
doi: 10.1007/s12029-009-9102-y pmid:19960278
27 Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, Swallow CJ, Verma S. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006; 20(3): 157–163
pmid:16550259
28 Stratopoulos C, Soonawalla Z, Piris J, Friend PJ. Hepatopancreatoduodenectomy for metastatic duodenal gastrointestinal stromal tumor. Hepatobiliary Pancreat Dis Int 2006; 5(1): 147–150
pmid:16481303
29 Liu SL, Zheng QC, Song ZF, Li W, Hu SB. Gastrointestinal stromal tumor of duodenum: a cause of upper gastrointestinal hemorrhage. Chinese-German J Clin Oncol 2010; 9(4): 243–245
doi: 10.1007/s10330-010-0026-6
30 van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005; 104(9): 1781–1788
doi: 10.1002/cncr.21419 pmid:16136600
31 Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Wo?niak A, Limon J, Siedlecki J, Grzesiakowska U, Kakol M, Osuch C, Polkowski M, G?uszek S, Zurawski Z, Ruka W. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007; 14(7): 2018–2027
doi: 10.1245/s10434-007-9377-9 pmid:17473953
Related articles from Frontiers Journals
[1] Xinsen Xu,Kai Qu,Qing Pang,Zhixin Wang,Yanyan Zhou,Chang Liu. Association between telomere length and survival in cancer patients: a meta-analysis and review of literature[J]. Front. Med., 2016, 10(2): 191-203.
[2] Lan Wang,Jueheng Wu,Jie Yuan,Xun Zhu,Hongmei Wu,Mengfeng Li. Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo[J]. Front. Med., 2016, 10(1): 41-51.
[3] Eric C. H. Lai,Chung Ngai Tang. Robotic distal pancreatectomy versus conventional laparoscopic distal pancreatectomy: a comparative study for short-term outcomes[J]. Front. Med., 2015, 9(3): 356-360.
[4] Rui Zhu,Lin Shen,Caoyuan Wang,Yanping Yang,Rui Chen,Hen Fang,Xiaojuan Xu. A new minimally invasive treatment for anal fistula[J]. Front. Med., 2015, 9(1): 77-81.
[5] Yunfeng Fu, Xinyu Wang, Zimin Pan, Xing Xie. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases[J]. Front Med, 2014, 8(1): 91-95.
[6] Shu Zhang, Yinwei Li, Xianqun Fan. Application of endoscopic techniques in orbital blowout fractures[J]. Front Med, 2013, 7(3): 328-332.
[7] Renling Pei, Ye Xu, Yan Wei, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie. Association of SIPA1 545 C>T polymorphism with survival in Chinese women with metastatic breast cancer[J]. Front Med, 2013, 7(1): 138-142.
[8] Fangqin Ma, Qi Wang, Lihua Wang. Advances in the management of the surgical complications for congenital cataract[J]. Front Med, 2012, 6(4): 360-365.
[9] Junqing Wang, Lu Zhang, Weize Wu. Current progress on natural orifice transluminal endoscopic surgery (NOTES)[J]. Front Med, 2012, 6(2): 187-194.
[10] Jia Wei, Jiexiong Feng. Laparoscopic treatment of liver diseases in children[J]. Front Med, 2011, 5(4): 388-394.
[11] Jihui Ai, Pei Zhang, Lei Jin, Yufeng Li, Jing Yue, Ding Ma, Hanwang Zhang. Fertility outcome analysis after modified laparoscopic microsurgical tubal anastomosis[J]. Front Med, 2011, 5(3): 310-314.
[12] Ka Li, Zongguang Zhou, Zengrong Chen, Yi Zhang, Cun Wang. “Fast Track” nasogastric decompression of rectal cancer surgery[J]. Front Med, 2011, 5(3): 306-309.
[13] Hongyi Cui. Single incision laparoscopic cholecystectomy using the one-incision three-trocar technique with all straight instruments: how I do it?[J]. Front Med, 2011, 5(3): 283-287.
[14] Taiping Zhang, Xiao Du, Yupei Zhao. Laparoscopic surgery for pancreatic lesions: current status and future[J]. Front Med, 2011, 5(3): 277-282.
[15] Min ZHU, Xiang-Ning FU, Xiao-Ping CHEN. Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer[J]. Front Med, 2011, 5(1): 53-60.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed